Plasma type II phospholipase A2 levels are elevated in severe preeclampsia

Article Abstract:

Severe preeclampsia appears to associate with elevated blood levels of type II phospholipase A2 (PLA2). PLA2 is an enzyme in the metabolic pathway that makes prostaglandins such as prostacyclin. PLA2 is found in platelets, white blood cells, and blood vessel lining cells and is involved in the inflammatory process. Preeclampsia is a kind of high blood pressure found in pregnant women. Plasma levels of PLA2 were measured among 25 women with preeclampsia and compared with levels from 23 healthy pregnant women. Plasma samples from 10 additional women with preeclampsia and 10 healthy women were incubated with a culture of human umbilical-vein lining cells, and the culture medium was analyzed for prostacyclin. Mild preeclampsia had no effect, but severely preeclamptic women had levels of 19.9 nanograms per milliter versus 6.0 nanograms per milliliter among control women. Prostacyclin concentration averaged 8.6 nanograms per milliliter when umbilical cord cells were incubated with plasma from severely preeclamptic women versus 4.0 nanograms per milliliter among controls. However, PLA2 concentration was unaffected.

Phospholipases

---

Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies

Article Abstract:

A deficiency of a protein called placental growth factor may be partly responsible for some preeclampsia and fetal growth restriction, according to a study of 98 women. This protein can cause blood vessels to form and causes the placenta to develop. Both preeclampsia and fetal growth restriction are believed to be partly caused by an abnormal placenta.

Growth factors, Neovascularization, Fetal growth retardation, Placenta

---

Maternal serum activin A is not elevated before preeclampsia in women who are at high risk

Article Abstract:

Research has been conducted on serum activin A. The authors have tested the theory that serum activin A can predict preeclampsia in women, and the results have demonstrated that activin A cannot be used as a preeclampsia predictor because its levels are not activated with preeclampsia.

Research and Development in the Physical, Engineering, and Life Sciences, Science & research, Research and Testing Services, New Zealand, Gynecological R&D, Health aspects, Research, Analysis, Diagnosis, Pregnant women, Serum, Blood serum, Risk factors (Health), Obstetrics, Gynecological research

Similar abstracts:

• Abstracts: Abnormal endothelial cell function of resistance arteries from women with preeclampsia. Longitudinal evaluation of markers of endothelial cell dysfunction and hemostasis in treated antiphospholipid syndrome and in healthy pregnancy
• Abstracts: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis
• Abstracts: Small steps or a giant leap for the uninsured? Forecast for US uninsured remains gloomy. Expanding insurance coverage through tax credits, consumer choice, and market enhancement
• Abstracts: Delegates rally to knock out cuts in Medicare payments. Doctors seek long-term Medicare pay formula fixes
• Abstracts: Skilful communication is necessary for quality care; Jennifer Campbell describes how an article helped her communicate with people with dementia

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.